The Line Item Nobody Puts in the Deck
There are two ways to sell a women's health product. One requires clinical evidence and FDA review. The other requires neither, and in January the FDA made it wider. Capital funds both on roughly the same terms.
When a gynecologist testified at the September 16, 2026 Senate Special Committee on Aging hearing on menopause that much of her time goes to counseling patients about supplements and unregulated products marketed online, she was describing a venture capital reality.
There are two ways to sell a women's health product. One requires clinical evidence and FDA review. The other requires neither, and in January the FDA made the second route wider.
Capital funds both on roughly the same terms.
Two companies can sell a women's health product into the same market on completely different terms.
One runs a clinical study, submits to the FDA, and waits a year or more for a decision, paying for the science out of its own accounts. Natural Cycles took this path to secure De Novo clearance for digital contraception. Proov ran its own trial and reached market through 510(k) clearance for at-home progesterone tracking. The other writes its claims carefully, stays inside the general wellness policy, and sells without generating evidence that the product works. Cycle and hormone insights ship under wellness language across most of the consumer hardware in this category, and a product can infer hormonal shifts without ever filing a clinical study.
Investors fund both. Nothing in a standard diligence process prices the gap between them.
On January 6, 2026, the FDA made the second route wider.
The revised General Wellness policy for low-risk devices replaced a 2019 version that said nothing about products that sense or infer physiologic parameters. The new one addresses them directly.
Those products can sit outside device regulation if they are noninvasive, not intended to diagnose or treat, not a substitute for a cleared device, carry no claims that guide clinical management, and do not output values that mimic clinical ones unless those values are validated.
That covers most of what women's health hardware is built to do, and the change moved through the category almost unremarked.
The policy is explicit about what it does not mean. A product falling under it has not been shown to be safe or effective for its intended use. FDA's device center states it does not intend to examine low risk general wellness products at all, including whether they are devices, whether they meet premarket requirements, whether they meet labeling rules, and whether they meet quality system requirements.
Guidance is not law either. FDA's own documents say guidances describe current thinking and do not establish legally enforceable responsibilities.
A parallel gap sits in the language companies use. Saying a product is FDA registered can be literally true and convey nothing. Registration means a company told the agency it exists and listed a product. Under 21 CFR 807.39, registering an establishment does not denote FDA approval of the establishment or the device, and FDA warning letters state that references to registration which create an impression of official approval, clearance or endorsement are misleading and constitute misbranding. Most buyers cannot tell the two apart on a product page.
Neither, in practice, can many of the people writing checks.
The regulated path costs what it costs. A novel diagnostic or biosensor in women's health usually has no legally marketed predicate, which rules out the 510(k) route and sends the company to De Novo classification. FDA's performance goal there is a decision within 150 review days, and review days exclude time the submission sits on hold.
A 2025 analysis of FDA data covering 2015 to 2024 put the mean decision time for standard De Novo requests at 338 days. Regulatory practitioners describe 12 to 18 months from submission to grant order once deficiency letters are counted.
For genuinely new technology, the review clock is not the binding constraint anyway. The clinical study is, and no performance goal shortens that.
The draft MDUFA VI commitment letter, summarized in the Federal Register on July 8, 2026, tightens the De Novo goal to 150 FDA days for 90 percent of requests, up from 70 percent. It also resets the 510(k) total time to decision ladder, starting at 128 days in fiscal 2028 and not returning to 112 days until fiscal 2032. Review predictability improves. Total time does not.
A company that runs a prospective trial, funds it before revenue, and waits out that process is carrying a cost that a company in the wellness lane never incurs. Same customer, same shelf, same box on a market map, different cost basis entirely. None of it surfaces in diligence. Term sheets have no line called evidentiary burden, and regulatory risk usually gets read as a binary question about whether a company might receive a letter, rather than as a measure of what it spent to be allowed to say what it says.
Two companies raising at the same stage can therefore be carrying very different amounts of scientific cost, and the one that spent more on evidence often looks worse on the metrics that attract funding, because the money went into a study instead of into growth.
FDA does draw a line. In July 2025 the agency sent a warning letter to a wearable manufacturer over blood pressure insights functionality, reasoning that blood pressure measurement is inherently tied to diagnosing hypertension. In September 2025 it issued a safety communication stating that blood pressure measuring devices require marketing authorization and fall outside the general wellness policy. The boundary sits where a product starts producing numbers a clinician would act on.
Most of this category is walking toward that boundary. Inferring hormonal state from temperature, heart rate variability and other signals is the technical premise of nearly every device being built in women's health right now. The January revision tells those companies they can stay outside device regulation as long as their outputs do not mimic clinical values without validation, which is a product design constraint and a fork in the cost structure at the same time.
The line item is the cost of demonstrating that the product works, and it falls entirely on the companies that choose to demonstrate it. That choice got more expensive in January on a relative basis. Clearance did not get harder.
The alternative got easier. Until capital in this category treats evidence as an asset on the balance sheet rather than a drag on the burn rate, the cheapest women's health company to build will keep being the one that never has to prove anything.
The Luteal covers the business, science, and policy of women's health. Nothing here is medical advice. ---
Sources
Primary
FDA, "General Wellness: Policy for Low Risk Devices," revised guidance issued January 6, 2026, replacing the September 2019 version. Source for the treatment of products that sense, estimate, infer or output physiologic parameters, the qualifying conditions, the statement that inclusion does not establish a product is safe or effective, and the device center's statement that it does not intend to examine low risk general wellness products for device status or for compliance with premarket, labeling, quality system and reporting requirements.
FDA standard guidance language that guidances do not establish legally enforceable responsibilities.
21 CFR 807.39, and FDA warning letter language stating that references to establishment registration which create an impression of FDA approval, clearance, authorization, certification or endorsement are misleading and constitute misbranding.
FDA, "De Novo Classification Request," for the pathway definition, the absence-of-predicate trigger, and the 150 review day MDUFA decision goal with review days excluding additional information holds.
MDUFA performance goals, fiscal years 2023 through 2027, and the draft MDUFA VI commitment letter as summarized in the Federal Register, July 8, 2026, for the 150 FDA days for 90 percent of De Novo requests goal and the 510(k) total time to decision ladder.
FDA warning letter to a wearable manufacturer regarding blood pressure insights functionality, July 2025, and FDA safety communication on blood pressure measuring devices, September 2025.
FDA De Novo clearance of Natural Cycles as a digital contraceptive, 2018, and the company's subsequent 510(k) covering wrist temperature input from consumer hardware.
MFB Fertility 510(k) clearance for at-home PdG testing, 2020, and the company's verification and usability study registered on ClinicalTrials.gov as NCT03924440.
U.S. Senate Special Committee on Aging, "Half the Country, Zero Hearings: Meeting the Moment to End the Menopause Care Gap in America," September 16, 2026. Testimony of Coslett-Charlton on counseling patients about supplements and unregulated products marketed online. Quoted via reporting by Shefali Luthra and Isabela Espadas Barros Leal for The 19th, September 17, 2026.
Peer-reviewed
Analysis of FDA data covering 2015 to 2024 on accelerated access pathways in the US and EU, for the 338 day mean decision time for standard De Novo requests. Published 2025, available via PMC.
Practitioner sources
Regulatory consultancy analyses of De Novo timelines in practice, for the 12 to 18 month submission-to-grant range. Labeled as practitioner estimates in the copy.
---
The four changes, and nothing else
Your paragraph order, line breaks, one-line beats and section flow are untouched. So is the opening move from hearing testimony into the venture capital read.
1. The intro's attribution. The record does not show clinicians describing midlife care as a big business filled with unregulated products. It shows one gynecologist saying much of her time goes to counseling patients about supplements and unregulated products marketed online, and that women rely on social media rather than clinicians. The sentence keeps your shape and lands on the same phrase. Attributing to congressional testimony something nobody said is the one error in this piece that could not be walked back.
2. The 82% is out. No dataset exists that classifies femtech rounds by regulatory status, which is why I proposed building it. The nearest available evidence points the other way. New Market Pitch's June 2026 analysis of the prior 12 months found most capital went to validated companies, with larger rounds referencing FDA clearance, clinical trials and hospital partnerships. The sentence still says what you need it to say.
3. Oura is out. Oura published ovulation detection accuracy in JMIR, its temperature output feeds a cleared workflow under K202897, it shipped a proprietary women's health model in February 2026, and it built a 22-symptom Menopause Impact Scale. Naming it as the company that sells without generating evidence is wrong on the facts and hits your rule about implied negativity toward named companies. The replacement sentence makes the same point about the lane without a name in it. The "dozens of startups" count went with it, since an unsourced count invites one question.
4. Proov's pathway. It was 510(k), not De Novo, so "did the same" was inaccurate. Corrected and kept, since you put it back in. It does spend a little of the interview piece, so decide whether you want it here.
Still to check. Confirm Coslett-Charlton's full name and title from the committee's witness list, and confirm the quote against the committee video rather than press coverage.